Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
A combination of an extended-spectrum penicillin (piperacillin) and a beta-lactamase inhibitor (tazobactam). It provides coverage against Gram-positive, Gram-negative (including *Pseudomonas aeruginosa*), and anaerobic organisms.
## Primary Indications
* Moderate to severe infections, including hospital-acquired/ventilator-associated pneumonia.
* Intra-abdominal infections (e.g., peritonitis, appendicitis).
* Skin and skin structure infections.
* Complicated urinary tract infections.
* Febrile neutropenia (empiric therapy).
## Adult Dosing
The standard dose is **3.375 g (3 g piperacillin / 0.375 g tazobactam)** every 6 hours by intravenous infusion.
* For severe infections (including *Pseudomonas*): **4.5 g (4 g piperacillin / 0.5 g tazobactam)** every 6 hours.
* Administration: Typically infused over 30 minutes, though extended infusion (4 hours) is often utilized to optimize pharmacodynamics in critically ill patients.
* Maximum dose: **18 g (piperacillin component) per 24 hours**.
## Pediatric Dosing
Dosing is weight-based (calculated by piperacillin content):
* **Children ≥ 9 months:** 80–100 mg/kg/dose every 8 hours.
* **Neonates/Infants (< 9 months):** Dosing varies by age and birth weight; typically 75–100 mg/kg every 8 hours.
* Consult local institutional protocols or neonatal guidelines for specific gestational age adjustments.
## Dose Adjustments
* **Renal Impairment:** Requires dosage reduction based on creatinine clearance (CrCl).
* CrCl 20–40 mL/min: 2.25 g q6h.
* CrCl < 20 mL/min: 2.25 g q8h.
* Hemodialysis: Max 2.25 g q8h, plus a 0.75 g post-dialysis booster dose.
* **Hepatic Impairment:** No standard adjustment required, but use with caution.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, or any beta-lactam antibiotics (severe cross-reactivity with penicillins/cephalosporins).
* History of cholestatic jaundice or hepatic dysfunction associated with piperacillin-tazobactam.
## Adverse Effects
* **Common:** Diarrhea, nausea, constipation, headache, insomnia.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (anaphylaxis), hematologic effects (leukopenia, neutropenia, thrombocytopenia, especially with prolonged use >10 days), and elevated liver enzymes.
## Key Drug Interactions
* **Probenecid:** Increases serum concentrations of piperacillin by inhibiting renal tubular secretion.
* **Aminoglycosides:** Piperacillin can inactivate aminoglycosides *in vitro* if mixed in the same line; administer separated by at least 1 hour.
* **Warfarin:** May increase bleeding risk; monitor INR closely.
* **Methotrexate:** May increase methotrexate toxicity by reducing renal elimination.
## Monitoring
* **Renal Function:** Monitor baseline and periodically throughout therapy; adjust dose if CrCl declines.
* **Hematology:** CBC with differential (baseline and weekly for prolonged therapy >10 days due to risk of neutropenia).
* **Infection Response:** Monitor clinical symptoms and inflammatory markers (WBC, CRP, procalcitonin).
## Clinical Pearls
* **Sodium Load:** Each 4.5 g dose contains approximately 2.35 mEq (54 mg) of sodium; use caution in patients with sodium or fluid restrictions.
* **Pseudomonal Coverage:** Often used as a single agent for empiric treatment of *Pseudomonas*, but local antibiograms must be reviewed as resistance rates fluctuate.
* **Solubility:** Incompatible with lactated Ringer’s solution, aminoglycosides, and certain acidic solutions. Always check Y-site compatibility before administration.
***
**Educational Disclaimer:** This information is intended for clinical education and reference only. Dosing, contraindications, and drug interactions are subject to change. Always verify current prescribing information, institutional guidelines, and order sets before administering any medication.
